Enhancing reproducibility in cancer drug screening: How do we move forward?

Cancer Research

Volumn 74, Issue 15, 2014, Pages 4016-4023

  Hatzis, Christos ^a,b   Bedard, Philippe L ^i,j   Birkbak, Nicolai J ^k   Beck, Andrew H ^c   Aerts, Hugo J W L ^d,f   Stern, David F ^a,b   Shi, Leming ^g,l,m   Clarke, Robert ^h   Quackenbush, John ^d,e   Haibe Kains, Benjamin ^i,j  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Harvard Center for Cancer Biology   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^l FUDAN UNIVERSITY   (China)

^m Center for Translational Medicine   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; TUMOR MARKER; VEMURAFENIB; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; CANCER CELL LINE; CANCER SCREENING; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CYTOTOXICITY ASSAY; GENE EXPRESSION PROFILING; GENETIC CONSERVATION; GENETIC VARIABILITY; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MELANOMA; MUTATIONAL ANALYSIS; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; TRANSCRIPTOMICS; DRUG DEVELOPMENT; DRUG SCREENING; PHARMACOGENETICS; PROCEDURES; STANDARDS;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS;

EID: 84905454959     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0725     Document Type: Review

References (41)

1. Bredel M, Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 2004;5:262-75.
2. Drews J. Drug discovery: a historical perspective. Science 2000;287:1960-4.
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
4. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
5. Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, et al. Inconsistency in large pharmacogenomic studies. Nature 2013;504:389-93.
6. Jang IS, Neto EC, Guinney J, Friend SH, Margolin AA. Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. Pac Symp Biocomput 2014;19:63-74.
7. Pharmaceutical Reserarch and Manufacturers of America. More than 900 medicines and vaccines in clinical testing offer new hope in the fight against cancer. Medicines in development for cancer 2012. Available from: http://www.phrma.org/research/new-medicines.
8. Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009;15:406-20.
9. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10:514-23.
10. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
11. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 2010;363:1693-703.
12. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, et al. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 2013;3:52-67.
13. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 2011;10:188-95.
14. Walters WP, Namchuk M. Designing screens: how to make your hits a hit. Nat Rev Drug Discov 2003;2:259-66.
15. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D, et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A 2006;103:3153-8.
16. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol 2006;24:167-75.
17. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, et al. Molecular target class is predictive of in vitro response profile. Cancer Res 2010;70:3677-86.
18. Matson SL, Chatterjee M, Stock DA, Leet JE, Dumas EA, Ferrante CD, et al. Best practices in compound management for preserving compound integrity and accurately providing samples for assays. J Biomol Screen 2009;14:476-84.
19. McDonald GR, Hudson AL, Dunn SM, You H, Baker GB, Whittal RM, et al. Bioactive contaminants leach from disposable laboratory plasticware. Science 2008;322:917.
20. Marx V. Pouring over liquid handling. Nat Methods 2014;11:33-8.
21. Ekins S, Olechno J, Williams AJ. Dispensing processes impact apparent biological activity as determined by computational and statistical analyses. PLoS ONE 2013;8:e62325.
22. Slater K. Cytotoxicity tests for high-throughput drug discovery. Curr Opin Biotechnol 2001;12:70-4.
23. Niles AL, Moravec RA, Riss TL. In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high-throughput screening. Curr Chem Genomics 2009;3:33-41.
24. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 1993;160:81-8.
25. Chan GK, Kleinheinz TL, Peterson D, Moffat JG. A simple highcontent cell-cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays. PLoS ONE 2013;8:e63583.
26. Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol 2013;9:708-14.
27. Chou T. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol 1974;10:235-47.
28. Ball CA, Sherlock G, Parkinson H, Rocca-Sera P, Brooksbank C, Causton HC, et al. Standards for microarray data. Science 2002;298:539.
29. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001;29:365-71.
30. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001;2:RESEARCH0032.
31. Bolstad B, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193.
32. Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010;11:733-9.
33. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-27.
34. Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 2012;135:301-6.
35. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, et al. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 2012;104:311-25.
36. Beck AH, Knoblauch NW, Hefti MM, Kaplan J, Schnitt SJ, Culhane AC, et al. Significance analysis of prognostic signatures. PLoS Comput Biol 2013;9:e1002875.
37. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, et al. The MicroArray quality control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006;24:1151-61.
38. Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajada A, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013;12:1416-29.
39. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;10:813-23.
40. Xia M, Huang R, Witt KL, Southall N, Fostel J, Cho MH, et al. Compound cytotoxicity profiling using quantitative high-throughput screening. Environ Health Perspect 2008;3:284-91.
41. Heiser LM, Wang NJ, Talcott CL, Laderoute KR, Knapp M, Guan Y, et al. Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol 2009;3:R31.